CN108218894A - A kind of cefoxitin sodium crystal-form compound - Google Patents
A kind of cefoxitin sodium crystal-form compound Download PDFInfo
- Publication number
- CN108218894A CN108218894A CN201810008535.1A CN201810008535A CN108218894A CN 108218894 A CN108218894 A CN 108218894A CN 201810008535 A CN201810008535 A CN 201810008535A CN 108218894 A CN108218894 A CN 108218894A
- Authority
- CN
- China
- Prior art keywords
- cefoxitin sodium
- power
- preparation
- form compound
- sodium crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/57—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with a further substituent in position 7, e.g. cephamycines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
The invention belongs to pharmaceutical technology fields, and in particular to the cefoxitin sodium crystal-form compound shown in a kind of formula (I).The compound is as shown in Figure 1 using the X ray powder diffractograms that Cu K alpha ray measurements obtain.Cefoxitin sodium crystal-form compound provided by the present invention is that have better stability, and normal temperature storage may be used, and effectively reduces storage and the transportation cost of the medicine.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to crystal-form compound and its preparation side to a kind of cefoxitin sodium
Method.
Background technology
Cefoxitin sodium (Cefoxitin Sodium) chemical name is：(6R, 7S) -3- (carbamoyloxymethyl) -7-
Methoxyl group -8- oxos -7- [2 (2- thienyls) acetylamino] -5- thia -1- azabicyclos [4.2.0] oct-2-ene -2- formic acid
Sodium salt.Its chemical structural formula is：
Cefoxitin sodium is that being developed by MSD Corp. of the U.S. for Chinese market was introduced into 1992 is a kind of completely new
Cephalosporins drug.The product has has a broad antifungal spectrum, to gram-positive bacteria, negative bacterium, anaerobic bacteria or aerobic bacteria
There is the features such as more strongly active, highly stable to β-interior phthalein amine enzyme, internal distribution is wide, infection diffusate drug concentration is high, separately
Outside since it is mainly excreted by kidney, toxic side effect is small, and tolerance is big.Clinically for peritonitis and other abdominal cavities
In interior, pelvic cavity, gynecological infection, septicemia, endocarditis, urinary tract infections (including gonorrhoea), respiratory tract infection, bone joint infection,
Skin soft-tissue infection.
Cefoxitin sodium clinically more is made into vein and intramuscular injectable formulations, and said preparation is poor there is stability, right
Light and heat is very unstable, and placing related substance for a long time increases, and turbid phenomenon occurs after dissolving, it is caused to be encountered on using
Many difficult, there are drug safety hidden danger.The country's at least 32 enterprise's production and sales cefoxitin sodium for injection at present, raw material
It is related to 5 manufacturing enterprises；Medical institutions at different levels generally use, and the consumption sum of 2011~2015 years cefoxitin sodium for injection is equal
It it is first 10 of anti-infective medication, therefore its product quality is larger to the security implication of public's medication.
2015 editions《Chinese Pharmacopoeia》Provide cefoxitin sodium and cefoxitin sodium for injection storage requirement for " sealing, cool
It is preserved at dark drying ".But in intermediate links, it can not all ensure refrigeration house storage or even shady and cool condition is not achieved, especially pass through
Ji low developed area and most of grass roots, drug are placed on usual terms, storage at normal temperature, and drug active ingredient can accelerate
Degradation, safety and curative effect can all reduce.Therefore in view of the characteristics of the powerful market demand of the product and its poor stability, have very much
Necessity further improves the stability of the product.
It is well known that organic drug crystal is molecular crystal mostly, different crystal forms can be obtained due to crystallization condition difference,
This phenomenon is known as polymorphic.The crystal form of drug is different, their physical property such as density, fusing point, hardness, appearance, solubility
With the significant difference of dissolution rate etc..The polymorphic of drug also to drug quality (physicochemical property and stability) and faces
Bed curative effect also has large effect, and the polymorphic for studying drug is conducive to that drug is transformed, and improves clinical efficacy, and it is secondary anti-to mitigate poison
It should.Therefore, in recent years, the polymorphism of drug has caused very big attention both domestic and external.
People are more to the novel crystal forms research of Cefoxitin, to solve the problems, such as stability difference existing for the kind.Document
" cefoxitin sodium stability improvement " (Wei Qingjie, Hebei chemical industry, 2011) discloses the synthesis and crystallization of a kind of cefoxitin sodium
Method, so as to which the color grade for making cefoxitin sodium is improved；Document " improvement of cefoxitin sodium crystallization processes " (Wei Qingjie, Guangzhou
Chemical industry, 2011) by the screening to salt forming agent and organic solvent, the crystallization processes of cefoxitin sodium are optimized, are obtained
The cefoxitin sodium product that crystal form is good, quality is high, at low cost, yield are more than 95%.Improved new process uses three water vinegar
It is each in quality and stability, crystal form and product granularity etc. to make cefoxitin sodium for sour sodium salt-forming agent, acetone, methanol as solvent
The more former technique of aspect has a clear superiority, easy to operate, of low cost, is more suitable for industrialized production；Patent
CN201110258682.2 provides a kind of Cefoxitin sodium crystal, improves the steady dissolution of cefoxitin sodium；Patent
CN201210514291.7 provides a kind of Cefoxitin sodium crystal, improves the moisture pick-up properties of cefoxitin sodium；Patent
CN201310268592.0 provides a kind of Cefoxitin sodium crystal, improves the stability and mobility of cefoxitin sodium；Specially
Sharp CN201410071491.9 provides a kind of Cefoxitin sodium crystal, improves cefoxitin sodium stability and hygroscopicity etc.；
Patent CN201410071491.9 provides a kind of Cefoxitin sodium crystal, improves cefoxitin sodium stability.But above-mentioned crystalline substance
Type cannot meet the requirement that cefoxitin sodium is preserved in interior room temperature of entire shelf-life (24 months).Hebei University of Science and Technology master discusses
Literary " synthesis of cefoxitin sodium and stability study " provides a kind of synthetic method, the cefoxitin sodium knot prepared using the method
Crystalline substance can be more stable under the storage of relative humidity 60% ± 10% at 25 DEG C ± 2 DEG C, but does not also provide the shelf-life (24 months)
Whole investigation data.
Therefore, in the market still it is necessary to research and develop a kind of Cefoxitin sodium novel crystal form, cefoxitin sodium original is further improved
Expect medicine or the thermal stability of its preparation, reduce it and preserve difficulty, reduce its storage, transportation cost, and ensure clinical application safety.
Invention content
The present inventor to cefoxitin sodium after a large amount of research has been carried out, by changing recrystallisation solvent, crystallization condition system
A kind of cefoxitin sodium crystal-form compound of the crystalline structure different from the prior art was obtained, and surprisingly finds the new cephalo
The thermal stability of western fourth sodium crystal compound is substantially better than the cefoxitin sodium of the prior art, and room temperature can be realized within the shelf-life
Storage, content and related substance can meet pharmacopoeial requirements, and the polymer content in product is also within control range.
The purpose of the present invention is to provide a kind of new Cefoxitin crystal-form compounds, and the crystal-form compound is compared to existing
Technology has improved thermal stability.
Meanwhile the present invention also aims to provide a kind of preparation comprising the cefoxitin sodium crystal-form compound and
Preparation method.
To achieve the above object, the present invention adopts the following technical scheme that：
A kind of cefoxitin sodium crystal-form compound shown in formula (I),
Wherein, the X-ray powder diffraction that the cefoxitin sodium crystal-form compound is obtained using Cu-K alpha ray measurements
Spectrogram is as shown in Figure 1.
Further, the X-ray powder diffraction spectral data of the Cefoxitin sodium crystal is as follows：
A kind of preparation for including the cefoxitin sodium crystal-form compound, the dosage form of the preparation is powder-injection.
The present invention relates to the preparations for including cefoxitin sodium crystal-form compound in some embodiments, are by this sterile hair
Bright cefoxitin sodium crystal-form compound direct packaging is prepared into different size.
The present invention relates to the preparation for including cefoxitin sodium crystal-form compound in some embodiments, also comprising other pharmacy
Upper common auxiliary material.
What cefoxitin sodium crystal-form compound of the present invention and its preparation can infect caused by treatment sensitive bacterial is prepared
It is applied in drug, the infection includes respiratory tract infection, endocarditis, peritonitis, pyelonephritis, urinary tract infections, septicemia
And bone, joint, Skin and soft tissue infection.
The present invention furthermore provides the preparation method of the cefoxitin sodium crystal-form compound, and this method includes as follows
Step：
Cefoxitin sodium crude product is taken to be added in the water of 2 times of weight, heating is stirred to complete molten that cefoxitin sodium is water-soluble
Liquid adds the activated carbon of 0.1 times of weight of cefoxitin sodium crude product, stirs 30 minutes, filters while hot, and filtrate is controlled 85
DEG C, the volume of the mixed solution of absolute ethyl alcohol and methanol, the mixed solution absolute ethyl alcohol and methanol is slowly added dropwise under stiring
Than being 12:1, until muddiness occurs in solution, stir to room temperature, continue stirring no less than 30 minutes, stand overnight, filter, it is dry.
The cefoxitin sodium crystal-form compound and the related substances of comparative example crystal form samples of the present invention, content and polymer
Detection method uses《Chinese Pharmacopoeia》In relation to detection of the cefoxitin sodium in relation to substance, content in (2015) page 250~252
Method；The detection of polymer is using document " efficient molecular exclusion chromatography measures cefoxitin sodium for injection polymer " (China
The hospital pharmacy magazine phase of volume 33 the 19th end of the year 2013, page 1651~1652) in method.
Description of the drawings
Fig. 1：The X-ray powder diffraction pattern of cefoxitin sodium crystal-form compound made from the embodiment of the present invention 1.
Specific embodiment
Following is that in conjunction with specific embodiments and experimental example, the present invention is further explained.But these embodiments are only limitted to illustrate
The present invention rather than for limiting the scope of the invention.The experimental method of specific experiment condition is not specified in the following example, leads to
Often according to normal condition.
Embodiment 1：Cefoxitin sodium crystal-form compound
Cefoxitin sodium crude product 50g is taken to be added in the water of 100mL, heating is stirred to complete molten that cefoxitin sodium is water-soluble
Liquid adds 5g activated carbons, stirs 30 minutes, filters while hot, and filtrate is controlled at 85 DEG C, anhydrous second is slowly added dropwise under stiring
The volume ratio of the mixed solution of alcohol and methanol, the mixed solution absolute ethyl alcohol and methanol is 12:1, until there is muddiness in solution,
Stirring continues stirring 30 minutes, stands overnight, filter, be drying to obtain, white powder crystal to room temperature.It is detected with HPLC pure
Spend is 99.4%.
The X-ray powder diffraction collection that obtained cefoxitin sodium crystal-form compound is obtained using Cu-K alpha ray measurements
As shown in Figure 1.
Comparative example 1：
Cefoxitin sodium crystal is prepared by 201110258682.2 specification embodiments of patent CN, 1 method, obtains white crystals
Property powder, with HPLC detection purity be 99.9%, the product be 1 sample of comparative example.
Comparative example 2：
Cefoxitin sodium crystal is prepared by 201310268592.0 specification embodiments of patent CN, 1 method, obtains white powder
End is 99.8% with HPLC detection purity, which is 2 sample of comparative example.
Comparative example 3：
Cefoxitin sodium crystal is prepared by 201210514291.7 specification embodiments of patent CN, 1 method, obtains white powder
End is 99.5% with HPLC detection purity, is 3 sample of comparative example.
Comparative example 4：
Cefoxitin sodium crystal is prepared by 1 method of patent CN201410071491.9 specifications embodiment, obtains white crystals
Property powder, with HPLC detection purity be 99.6%, be 4 sample of comparative example.
Comparative example 5：
Cefoxitin sodium crystal is prepared by 1 method of patent CN201510875107.5 specifications embodiment, obtains white crystals
Property powder, with HPLC detection purity be 99.7%, be 5 sample of comparative example.
Comparative example 6:
By the method that document Hebei University of Science and Technology Master's thesis " synthesis of cefoxitin sodium and stability study " provides, head
The western butyric acid of spore reacts in acetone ethanol mixed solution with sodium iso-octoate to be prepared Cefoxitin sodium crystal and (is specifically shown in the paper the 16th
Page), off-white color crystalline powder is obtained, is 99.8% with HPLC detection purity, is 6 sample of comparative example.
Stability test
The purpose of stability test is to investigate the rule that product changes over time under the influence of temperature, humidity, light, is medicine
Product production, packaging, traffic condition provide scientific basis.
1：Influence factor is tested
Influence factor is placed using three conditions, and high-temperature sample experiment carries out under the conditions of being 60 DEG C, high wet test in 25 DEG C,
It is carried out under the conditions of RH92.5%, illumination is placed in 5000Lx, is sampled respectively at 5,10 days, measures indices.Experimental result is shown in
Table 1：
1 sample effects factorial experiments result of table
Conclusion：By influence factor result of the test it is found that 1 sample of embodiment, 2 sample of comparative example, 4 sample of comparative example are in height
Under wet, high temperature, illumination condition, total miscellaneous and single miscellaneous, the changes of contents of polymer is little；It is 1 sample of comparative example, 3 sample of comparative example, right
The content of 5 sample of ratio and 6 sample of the comparative example polymer under high humidity, high temperature, illumination condition increases very fast.
Cefoxitin sodium is beta-lactam antibiotic, research shows that, the anaphylactic type mistake that beta-lactam antibiotic causes
Simultaneously non-antibiotic medicament is caused in itself for quick reaction, but related with high molecular polymer present in drug.Cephalo west of the present invention
Fourth sodium crystal total miscellaneous, single miscellaneous and polymer content in influence factor experiment is relatively stablized, and can reduce clinical practice risk.
2：Accelerated test
With reference to influence factor result of the test, and listing product holding conditions are combined, the condition for drafting accelerated test is 40 DEG C ± 2
DEG C, RH 75% ± 5%.Test specimen is placed in 40 DEG C ± 2 DEG C of temperature, relative humidity RH by the sample of simulation listing packaging
In 75% ± 5% constant temperature, constant humidity cabinet, indices are measured respectively at 0,1,2,3, June, accelerated test result see the table below.
2 sample accelerated test result of table
Conclusion：By accelerated test result it is found that being examined under the conditions of 40 DEG C ± 2 DEG C of temperature, relative humidity RH 75% ± 10%
Under the conditions of examining 6 months, comparative example 1, comparative example 3, comparative example 5, the miscellaneous variation of total miscellaneous and list are little, but compare
Example sample polymer content increases apparent；Total miscellaneous, the single miscellaneous and polymer increase of comparative example 6 is larger；1 sample of embodiment,
Total miscellaneous, the single miscellaneous and polymer variation of 2 sample of comparative example, 4 sample of comparative example is less, substantially corresponding to influence factor result of the test.
3：Long term test
Since sample accelerated test is carried out under the conditions of 40 DEG C ± 2 DEG C, sample is put by the sample of simulation listing packaging
Stored in 25 DEG C ± 2 DEG C of temperature, the constant temperature of relative humidity RH 60% ± 10%, constant humidity cabinet, respectively at 0,3,6,9,12,18,
It samples within 24 months, measures indices.Long-term test results see the table below.
3 sample long-term test results of table
Conclusion：It is well known that the Chinese Pharmacopoeia quality standard that cefoxitin sodium has been expressly recited in version second in 2015,
It is required that related substance is always miscellaneous to be not greater than 4%, list is miscellaneous to be not greater than 0.5%.In 25 DEG C ± 2 DEG C of temperature, relative humidity RH 60%
It is investigated 24 months under the conditions of ± 10%, 1 sample of comparative example and the comparative example 5 sample data of 24th month show that its polymer increases
It is larger, there is clinical application risk；2 sample of comparative example was relatively stablized at first 12 months, but in rear product in December accelerated decomposition, and the 24th
The single miscellaneous index for not met China's standards of pharmacopoeia requirement at a month；3 sample list of comparative example is miscellaneous just to be surpassed at 12nd month
States Pharmacopoeia specifications index is gone out, and the increased speed of its polymer is also very fast；4 sample list of comparative example is miscellaneous to exceed pharmacopeia at 24th month
Set quota and the increased speed of its polymer；6 sample of comparative example the 18th month list it is miscellaneous, total miscellaneous have exceeded pharmacopeia rule
Determine index, and the increased speed of its polymer is also very fast, clinical application increased risk.Above-mentioned 1~6 sample shelf-life of comparative example
After (in 24 months) room temperature preserves, sample either cannot meet National Pharmacopeia standard or polymer content is significantly increased, and has and faces
Bed drug risk.
The cefoxitin sodium crystal-form compound of the present invention is in long term test (25 DEG C ± 2 DEG C of temperature, relative humidity RH 60%
Stored in ± 10% constant temperature, constant humidity cabinet) in stability it is preferable, 24th month clarity of solution, color, it is single it is miscellaneous, it is total it is miscellaneous
Meet the related request of Chinese Pharmacopoeia, and polymer content is also more stable.Long-term stable experiment is prompted, the western fourth of spore of the present invention
Sodium crystal compound can preserve at normal temperatures, and clinical application risk is smaller.
It should be understood that after reading the above teachings of the present invention, those skilled in the art can make the present invention
Various changes or modification, these equivalent forms also fall within the scope of the appended claims of the present application.
Claims (9)
1. the cefoxitin sodium crystal-form compound shown in a kind of formula (I),
It is characterized in that, the cefoxitin sodium crystal-form compound is spread out using the X-ray powder that Cu-K alpha ray measurements obtain
It is as shown in Figure 1 to penetrate collection of illustrative plates.
2. a kind of preparation for including the 1 cefoxitin sodium crystal-form compound of power, it is characterised in that the dosage form of the preparation is powder
Injection.
3. a kind of preparation as described in power 2, it is characterised in that the preparation is by the sterile 1 cefoxitin sodium crystal form chemical combination of power
Object direct packaging is into the preparation of different size.
4. a kind of preparation as described in power 2, it is characterised in that the preparation also includes other pharmaceutically common auxiliary materials.
5. a kind of cefoxitin sodium crystal-form compound as described in power 1 is in the drug infected caused by preparing treatment sensitive bacterial
Application.
6. a kind of application of preparation as described in power 2, power 3 or power 4 in the drug infected caused by preparing treatment sensitive bacterial.
7. it is a kind of power 5 as described in application, it is characterised in that the infection include respiratory tract infection, endocarditis, peritonitis,
Pyelonephritis, urinary tract infections, septicemia and bone, joint, Skin and soft tissue infection.
8. it is a kind of power 6 as described in application, it is characterised in that the infection include respiratory tract infection, endocarditis, peritonitis,
Pyelonephritis, urinary tract infections, septicemia and bone, joint, Skin and soft tissue infection.
9. a kind of preparation method of the cefoxitin sodium crystal-form compound as described in power 1, it is characterised in that comprise the following steps：Take head
The western fourth sodium crude product of spore is added in the water of 2 times of weight, and heating, stirring obtain Cefoxitin sodium water solution to entirely molten, add cephalo
The activated carbon of 0.1 times of weight of western fourth sodium crude product is stirred 30 minutes, is filtered while hot, filtrate is controlled at 85 DEG C, under stiring slowly
The volume ratio of the mixed solution of dropwise addition absolute ethyl alcohol and methanol, the mixed solution absolute ethyl alcohol and methanol is 12:1, until molten
There is muddiness in liquid, stirs to room temperature, continues stirring no less than 30 minutes, stands overnight, filters, dry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810008535.1A CN108218894A (en) | 2018-01-04 | 2018-01-04 | A kind of cefoxitin sodium crystal-form compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810008535.1A CN108218894A (en) | 2018-01-04 | 2018-01-04 | A kind of cefoxitin sodium crystal-form compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108218894A true CN108218894A (en) | 2018-06-29 |
Family
ID=62642845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810008535.1A Pending CN108218894A (en) | 2018-01-04 | 2018-01-04 | A kind of cefoxitin sodium crystal-form compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108218894A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114853786A (en) * | 2022-05-07 | 2022-08-05 | 华北制药河北华民药业有限责任公司 | Preparation method of cefoxitin sodium powder |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102295654A (en) * | 2011-08-10 | 2011-12-28 | 江西新先锋医药有限公司 | Cefoxitin compound and composition thereof |
| CN103304582A (en) * | 2013-06-28 | 2013-09-18 | 四川省惠达药业有限公司 | Cefoxitin sodium compound, preparation method and pharmaceutical composition thereof |
| CN103601739A (en) * | 2013-11-26 | 2014-02-26 | 悦康药业集团有限公司 | Cefoxitin sodium compound and preparation method thereof |
| CN105287600A (en) * | 2015-12-03 | 2016-02-03 | 南京多宝生物科技有限公司 | Gram-negative bacterium-resistant cefoxitin sodium freeze-dried powder for injection |
-
2018
- 2018-01-04 CN CN201810008535.1A patent/CN108218894A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102295654A (en) * | 2011-08-10 | 2011-12-28 | 江西新先锋医药有限公司 | Cefoxitin compound and composition thereof |
| CN103304582A (en) * | 2013-06-28 | 2013-09-18 | 四川省惠达药业有限公司 | Cefoxitin sodium compound, preparation method and pharmaceutical composition thereof |
| CN103601739A (en) * | 2013-11-26 | 2014-02-26 | 悦康药业集团有限公司 | Cefoxitin sodium compound and preparation method thereof |
| CN103804397A (en) * | 2013-11-26 | 2014-05-21 | 悦康药业集团有限公司 | Cefoxitin sodium compound and preparation method thereof |
| CN105287600A (en) * | 2015-12-03 | 2016-02-03 | 南京多宝生物科技有限公司 | Gram-negative bacterium-resistant cefoxitin sodium freeze-dried powder for injection |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114853786A (en) * | 2022-05-07 | 2022-08-05 | 华北制药河北华民药业有限责任公司 | Preparation method of cefoxitin sodium powder |
| CN114853786B (en) * | 2022-05-07 | 2024-01-12 | 华北制药河北华民药业有限责任公司 | Preparation method of cefoxitin sodium powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013285085B2 (en) | Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof | |
| CN103269587A (en) | New forms of rifaximin and uses thereof | |
| CN104650114A (en) | Forms of rifaximin and uses thereof | |
| CN102180890B (en) | Cefathiamidine hydrate and preparation method and application thereof | |
| CN102180889A (en) | Ceftizoxime sodium crystalline hydrate and preparation method and application thereof | |
| CN101167730B (en) | Compound betamethasone suspension injection | |
| CN108218894A (en) | A kind of cefoxitin sodium crystal-form compound | |
| AU2012389714B2 (en) | Cocrystal of piperacillin sodium and sulbactam sodium and preparation method thereof, as well as pharmaceutical compositions containing same and uses thereof | |
| CN108047253A (en) | A kind of Ceftriaxone Sodium crystal-form compound | |
| CN103304604B (en) | Clindamycin phosphate compound and preparation method and pharmaceutical composition thereof | |
| JP4896401B2 (en) | Ursolic acid-soybean lecithin freeze-dried nanoparticle injection and method for producing the same | |
| CN103655460B (en) | Injection medicinal composition containing aztreonam, as well as preparation method and application thereof | |
| CN103145603B (en) | Carbazochrome sodium sulfonate compound and medical composition thereof | |
| CN107746423B (en) | Ergosta-7, 22-diene-3-ketoxime, preparation method thereof and application thereof in preparation of antibacterial drugs | |
| CN107652306A (en) | A kind of Cefuroxime Sodium crystal-form compound | |
| CN106366099B (en) | A kind of anti-infectives Ceftriaxone Sodium crystalline compounds and preparation method thereof | |
| CN103450086A (en) | Ozagrel compound, preparation method and pharmaceutical composition of ozagrel compound | |
| CN110041347A (en) | Brizolina noval chemical compound and combinations thereof and purposes | |
| CN103724359B (en) | A kind of amorphous cefotetan acid and prepared the method for Cefotetan Disodium and containing the pharmaceutical composition of this Cefotetan Disodium by it | |
| CN106588954B (en) | A kind of anti-infectives amoxycillin crystalline compounds and combinations thereof | |
| CN106279312B (en) | A kind of azithromycin compound and combinations thereof | |
| CN106588953B (en) | A kind of anti-infectives cefadroxil crystal-form compound and combinations thereof | |
| CN102228460A (en) | Antibacterial composition and preparation method | |
| CN108434461B (en) | Beta-cyclodextrin inclusion compound of pyrazinamide and isoniazid rifamycin hydrazone and preparation method thereof | |
| CN106432275A (en) | Method for preparing crystalline ceftriaxone sodium compound as drug for treating surgical infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180629 |